BioLife Solutions, Inc. (BULLETIN BOARD: BLFS) , a leading manufacturer and marketer of cryopreservation solutions for the preservation of cells and tissues at low temperatures, announced today that veteran medical technology executive Raymond W. Cohen has been appointed to its Board of Directors, effective immediately. Cohen fills a vacancy on the Board, increasing the size of the Board to five Directors.

Cohen, 47, is an accredited director and currently serves as Chief Executive Officer of Laguna Hills, CA-based Symphony Medical, Inc., a venture capital backed privately-held developer of biologic solutions for the treatment of cardiac conduction abnormalities. Cohen also serves as the Chairman of Board of Directors of Bothell, WA-based Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products formed by the September merger of Quinton Cardiology Systems, Inc., and Cardiac Science, Inc., where Cohen served as Chief Executive Officer for nine years. Cohen also serves as a member of the Board of Directors of Syncroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO. He is a member of the Advisory Board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.

BioLife Solutions Chief Executive Officer John Baust said, "We're confident that we will benefit greatly from Ray's 25 years of leadership and entrepreneurial experience in healthcare. He has expertise in areas that are critical to the growth of BioLife including strategic alliances, new product development capital raising and regulatory compliance. We look forward to Ray's contributions as BioLife executes on our plan to expand our business in the growing field of human cell and tissue engineering."

About BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of cryopreservation solutions, which preserve cells and tissue in low temperature environments for extended periods. It markets HypoThermosol, CryoStor, and GelStor line of solutions directly to companies and labs engaged in pre-clinical research, and to academic institutions. The company's line of preservation solutions, based on its patented HypoThermosol technology, is composed of synthetic, aqueous solutions containing, in part, minerals and other elements found in human blood, which are necessary to maintain fluids and chemical balances throughout the body at near freezing temperatures. These solutions significantly prolong cell, tissue, and organ viability, which in turn, improve clinical outcomes for new and existing cell, and tissue therapy applications, as well as for organ transplantation. In addition, the company provides contract-based services for the development of cryopreservation solutions and processes. For more information please visit BioLife Solutions website at www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

  Contact:  Allen & Caron Inc
            Jill Bertotti (investors)
            jill@allencaron.com
            Len Hall (media)
            len@allencaron.com
            949-474-4300

SOURCE: BioLife Solutions, Inc.